GlassScriptPhysician profile
Nicholas Peter Xenopoulos
NPI 1568548006
$774.49
in general payments reported to CMS, 2019-2025
10 companies · $98.32 in 2025
The $98.32 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $170 · 2021: $49.69 · 2022: $132 · 2023: $24.74 · 2024: $41.62 · 2025: $98.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $164.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $310.06 | 2019-2025 | General - Vascular Access |
| Janssen Pharmaceuticals, INC | $91.64 | 2022 | |
| Inari Medical, INC. | $73.40 | 2019 | |
| Abbott Laboratories | $71.79 | 2022-2024 | Mitraclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $62.28 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $52.52 | 2019 | |
| Medtronic, INC. | $49.69 | 2021 | |
| Gilead Sciences, INC. | $27.80 | 2019 | |
| Cardiva Medical, INC. | $18.14 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $17.17 | 2024 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Xenopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.